| Literature DB >> 8539548 |
N Gürses1, S Uysal, F Cetinkaya, I Işlek, A G Kalayci.
Abstract
Guillain-Barre syndrome is an acquired demyelinating polyneuropathy that is presumed to be immune-mediated. On the basis of this assumption, intravenous immunoglobulin (IVIG) has been used in the treatment of Guillain-Barre syndrome in recent years and found to be effective. To test this we performed a randomized study in patients with Guillain-Barre syndrome by giving IVIG (1 g/kg body weight per day over 2 consecutive days) in 9 children who were compared with 9 patients who were observed but not given specific therapy. We concluded that intravenous immunoglobulin is a safe and effective treatment for childhood Guillain-Barre syndrome which shortens the time to recovery.Entities:
Mesh：
Substances：
Year: 1995 PMID： 8539548 DOI： 10.3109/00365549509019016
Source DB: PubMed Journal: Scand J Infect Dis ISSN： 0036-5548